Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of middle east respiratory syndrome coronavirus

Journal of Virology

Volumn 87, Issue 24, 2013, Pages 13134-13140

  Gao, Jing ^a,b   Lu, Guangwen ^a   Qi, Jianxun ^a   Li, Yan ^a   Wu, Ying ^a   Deng, Yao ^c   Geng, Heyuan ^c   Li, Hongbin ^a   Wang, Qihui ^a   Xiao, Haixia ^d   Tan, Wenjie ^c   Yan, Jinghua ^a   Gao, George F ^a,b,c,d,e  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Tianjin Airport Economic Area   (China)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPTAD REPEAT 1 PROTEIN; HEPTAD REPEAT 2 PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS FUSION CORE PROTEIN; VIRUS PROTEIN; VIRUS SPIKE PROTEIN;

ALPHA HELIX; AMINO ACID SEQUENCE; ARTICLE; BIOCHEMISTRY; BIOPHYSICS; COMPLEX FORMATION; CONTROLLED STUDY; CORONAVIRUS; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; HUMAN; HUMAN CELL; MEMBRANE FUSION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PSEUDOTYPING; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION;

AMINO ACID SEQUENCE; CORONAVIRIDAE INFECTIONS; CORONAVIRUS; CRYSTALLIZATION; HEK293 CELLS; HUMANS; PROTEIN STRUCTURE, SECONDARY; REPETITIVE SEQUENCES, AMINO ACID; SEQUENCE HOMOLOGY, AMINO ACID; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS INTERNALIZATION;

EID: 84888052193     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02433-13     Document Type: Article

References (37)

1. Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C, Hoschler K, Brown K, Galiano M, Myers R, Pebody RG, Green HK, Boddington NL, Gopal R, Price N, Newsholme W, Drosten C, Fouchier RA, Zambon M. 2012. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill. 17(40):pii=20290. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20290.
2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367:1814-1820.
3. World Health Organization. 2013. Middle East respiratory syndrome coronavirus (MERS-CoV)-update. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/don/2013_07_29/en/index.html.
4. Weiss SR, Navas-Martin S. 2005. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 69:635-664.
5. Gao GF. 2007. Peptide inhibitors targeting virus-cell fusion in class I enveloped viruses, p 226-246. In Torrence PF (ed), Combating the threat of pandemic influenza:drug discovery approaches. John Wiley & Sons Inc, Hoboken, NJ.
6. Plemper RK. 2011. Cell entry of enveloped viruses. Curr. Opin. Virol. 1:92-100.
7. Lai MM, Perlman S, Anderson LJ. 2007. Coronaviridae, p 1305-1336. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
8. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Kramer-Kuhl A, Welsch K, Winkler M, Meyer B, Drosten C, Dittmer U, von Hahn T, Simmons G, Hofmann H, Pohlmann S. 2013. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J. Virol. 87:5502-5511.
9. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495:251-254.
10. Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, Zhang Y, Zhang W, Yuan Y, Bao J, Zhang B, Shi Y, Yan J, Gao GF. 2013. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500:227-231.
11. Chambers P, Pringle CR, Easton AJ. 1990. Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J. Gen. Virol. 71(Part 12):3075-3080.
12. Cohen C, Parry DAD. 1986. Alpha-helical coiled coils-a widespread motif in proteins. Trends Biochem. Sci. 11:245-248.
13. Xu Y, Lou Z, Liu Y, Pang H, Tien P, Gao GF, Rao Z. 2004. Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J. Biol. Chem. 279:49414-49419.
14. Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. 2004. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. U.S.A. 101:8455-8460.
15. Xu Y, Liu Y, Lou Z, Qin L, Li X, Bai Z, Pang H, Tien P, Gao GF, Rao Z. 2004. Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J. Biol. Chem. 279:30514-30522.
16. Eckert DM, Kim PS. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:777-810.
17. Jiang S, Lin K, Strick N, Neurath AR. 1993. HIV-1 inhibition by a peptide. Nature 365:113.
18. Wild C, Greenwell T, Matthews T. 1993. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 9:1051-1053.
19. Watanabe S, Takada A, Watanabe T, Ito H, Kida H, Kawaoka Y. 2000. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J. Virol. 74:10194-10201.
20. Zhu J, Xiao G, Xu Y, Yuan F, Zheng C, Liu Y, Yan H, Cole DK, Bell JI, Rao Z, Tien P, Gao GF. 2004. Following the rule:formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem. Biophys. Res. Commun. 319:283-288.
21. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326.
22. Read RJ. 2001. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr.DBiol. Crystallogr. 57:1373-1382.
23. Collaborative Computing Project, Number 4. 1994. The CCP4 suite:programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760-763.
24. Emsley P, Cowtan K. 2004. Coot:model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
25. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX:a comprehensive Pythonbased system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66:213-221.
26. Laskowski RA, Macarthur MW, Moss DS, Thornton JM. 1993. Procheck-a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26:283-291.
27. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S. 2004. Receptorbinding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies:implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 324:773-781.
28. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
29. Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. 2004. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem. Biophys. Res. Commun. 319:746-752.
30. Singh M, Berger B, Kim PS. 1999. LearnCoil-VMF:computational evidence for coiled-coil-like motifs in many viral membrane-fusion proteins. J. Mol. Biol. 290:1031-1041.
31. Xu Y, Zhu J, Liu Y, Lou Z, Yuan F, Cole DK, Ni L, Su N, Qin L, Li X, Bai Z, Bell JI, Pang H, Tien P, Gao GF, Rao Z. 2004. Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus. Biochemistry 43:14064-14071.
32. Lu G, Liu D. 2012. SARS-like virus in the Middle East:a truly bat-related coronavirus causing human diseases. Protein Cell 3:803-805.
33. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, Fouchier RA. 2012. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3(6):e00473-12. doi:10.1128/mBio.00473-12.
34. Imai M, Okada N, Okada H. 2000. Inhibition of HIV-1 infection by an intramolecular antisense peptide to T20 in gp160. Microbiol. Immunol. 44:205-212.
35. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
36. Cuzin L, Alvarez M. 2003. Enfuvirtide for prophylaxis against HIV infection. N. Engl. J. Med. 349:2169-2170. (Author's reply, 349:2169-2170.)
37. Root MJ, Kay MS, Kim PS. 2001. Protein design of an HIV-1 entry inhibitor. Science 291:884-888.